Verastem Reports Strong Pancreatic Cancer Trial Results, Advances KRAS Inhibitor to Phase 2
VSTM is trading near its 52-week low of $3.55 (15% above the low).
Summary
Verastem announced highly positive updated clinical trial results for its combination therapy in first-line metastatic pancreatic cancer, showing strong survival and response rates, and also initiated a Phase 2 registration-directed trial for its KRAS G12D inhibitor.
Key Events · Product Development and Regulatory · VSTM
-
Positive RAMP 205 Trial Results
Verastem announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a trial evaluating avutometinib plus defactinib in combination with standard-of-care chemotherapy in first-line metastatic pancreatic ductal carcinoma (mPDAC).
-
Strong Clinical Activity Demonstrated
With a median follow-up of 9.8 months, the combination therapy showed an 86% overall survival rate at 6 months, a 68% progression-free survival rate at 6 months, and a confirmed objective response rate of 52%.
-
Significant Tumor Shrinkage
The majority (83%) of patients in the Recommended Phase 2 Dose cohort experienced tumor shrinkage, with nine patients remaining on treatment.
-
Phase 2 Registration-Directed Trial Initiated
The first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G12D inhibitor, for patients with second-line mPDAC.
Analysis · VSTM · Life Sciences
These positive updated clinical results for a combination therapy in first-line metastatic pancreatic cancer are highly significant, especially given the company's previous disclosure of substantial doubt about its ability to continue as a going concern. Pancreatic cancer is notoriously difficult to treat, and the reported 86% overall survival rate at 6 months and 52% objective response rate are very encouraging for a Phase 1b/2a trial. This data could significantly improve investor confidence and future financing prospects, providing a potential lifeline for the company. Additionally, the initiation of a registration-directed Phase 2 trial for their KRAS G12D inhibitor further strengthens their pipeline and long-term outlook.
How filings like this one have moved
In the 30 days to Nov 4, 2026, 50% of the 206 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.71%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VSTM was trading at $4.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $352.4M. The 52-week trading range was $3.55 to $11.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.